Open an account

MiniMed Group

MMED · NASDAQ

$17.49−$0.30 (−1.69%)TodayMarket closed ·
Prev close $17.79

About MMED

MiniMed Group, Inc. engages in the development, manufacturing, and marketing of a wide range of medical devices and solutions for diabetes management. The company is headquartered in Northridge, California and currently employs 8,000 full-time employees. The company went IPO on 2026-03-06. Its fully integrated system addresses pain points for people with diabetes (PWD): health outcomes and complexity of diabetes management. The MiniMed 780G is its flagship AID system. The MiniMed 780G system uses its SmartGuard dosing algorithm technology, which automatically delivers basal insulin and auto-correction doses every five minutes based on sensor glucose readings. The MiniMed 780G consists of the MiniMed 780G insulin pump, the Simplera Sync CGM sensor, and the instinct sensor. Its platform of clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and a Smart Multiple Daily Injection (MDI) System. Its pipeline products are the MiniMed Flex, screenless insulin pump, next-generation Vivera dosing algorithm, and MiniMed Fit patch pump with extended wear.

Employees
8,000
Headquarters
Northridge, California
Listed
Mar 6, 2026
Sector
Health Care
Industry
Health Care Equipment & Supplies

MMED key statistics

Market cap
4.92B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
15.93M
Volume
10.86M
Open price
$18.04
High today
$18.13
Low today
$17.36
52 Week high
$24.43
52 Week low
$10.65

MiniMed Group (MMED) at a glance

MiniMed Group (MMED) last traded at $17.49, with a market cap of 4.92B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $17.36 and $18.13. The current price is 0.7% above the day's low and 3.5% below its high.

Volume so far is 10.86M shares, below the average of 15.93M shares a day.

Over the past year MiniMed Group has ranged from $10.65 to $24.43, and now sits 50% of the way up that range.

MiniMed Group met or beat analyst EPS estimates in 0 of the last 3 quarters. In Q1 FY27 it reported $0.00 per share against an estimate of $0.0952.

The average analyst price target is $26.52, 51.6% above the current price, from 16 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

81%of 16 analyst ratings say Buy
  • Buy81.3%
  • Hold18.8%
  • Sell0.0%
Price target · 14 analystsAvg $26.52
Low
$21.21
Now
$17.49
High
$30.45

MMED earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 3 quarters.

  1. Q3 FY26: reported -$0.47 per share against an estimate of $0.1613
  2. Q4 FY26: reported -$0.68 per share against an estimate of -$0.1735
  3. Q1 FY27: reported $0.00 per share against an estimate of $0.0952

MMED news

  • Press releasePRNewswire

    MiniMed Completes Separation from Medtronic

  • Press releasePRNewswire

    Medtronic Completes Separation of MiniMed Group, Inc.

  • Press releasePRNewswire

    Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer

  • Erica Kollmann

    Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse

  • Press releasePRNewswire

    Medtronic Announces Preliminary Results of MiniMed Group, Inc. Exchange Offer

  • Avi Kapoor

    Jim Cramer Doesn’t Like This Health Care Stock, Sees No Reason To Buy Rambus

  • Press releasePRNewswire

    Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.

  • Press releasePRNewswire

    Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes

Similar companies

Companies in the same industry as MiniMed Group

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.